A
Alvotech SA
NASDAQ:ALVO
Alvotech SA
NASDAQ:ALVO
Price:
13.34 USD
0.38%
Updated:
May 14, 2024
Section:
Relative Value
The Relative Value of one ALVO stock under the Base Case scenario is 31.78 USD. Compared to the current market price of 13.34 USD, Alvotech SA is Undervalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALVO
Relative Value
Base Case
31.78
USD
Undervaluation 58%
A
Valuation Multiples
Multiples Across Competitors
ALVO Competitors Multiples
Alvotech SA Competitors
Alvotech SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| LU |
A
|
Alvotech SA
NASDAQ:ALVO
|
3.6B USD | 38.1 | -6.5 | -13.8 | -12.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.9B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
166.1B USD | 5.6 | 44.1 | 18.6 | 30.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.9B USD | 11.1 | 30.2 | 24.5 | 25.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.6B USD | 8.2 | 27.9 | 22.6 | 25 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.1 | 21.8 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.9B USD | 3.1 | 173.4 | 7 | 9.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.2B USD | 9.6 | -8.3 | -9.1 | -8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.4B USD | 3.4 | 27.8 | 14.2 | 17.7 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
